In-vitro permeation of bevacizumab through human sclera: Effect of iontophoresis application

Silvia Pescina, Giulio Ferrari, Paolo Govoni, Claudio MacAluso, Cristina Padula, Patrizia Santi, Sara Nicoli

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used in ophthalmology (off-label) for the treatment of neovascularization in diseases such as diabetic retinopathy and age-related macular degeneration (wet form). Bevacizumab is currently administrated by repeated intravitreal injection, which can cause severe complications; a non-invasive delivery route is therefore desirable. The passive permeation of bevacizumab through isolated human sclera was evaluated and the iontophoretic technique was explored as a method to enhance its transscleral transport in vitro. Methods Bevacizumab was fluorescently labelled using fluorescein isothiocyanate (FITC). Permeation experiments were conducted for 2 h in Franz-type diffusion cells using human sclera as the barrier. The donor compartment contained FITC-bevacizumab (2.5 mg/ml) in phosphate-buffered saline at pH 7.4. In the iontophoretic experiments, a current intensity of 2.3 mA (current density 3.8 mA/cm2) was applied. The permeation samples were analysed with a fluorescence detector (excitation and emission wavelengths were 490 and 520 nm, respectively). The stability of FITC-bevacizumab conjugate was checked by thin layer chromatography. Key findings The main finding of this work is that anodal iontophoresis can significantly enhance bevacizumab transport through isolated human sclera (enhancement factor 7.5), even though the drug is essentially uncharged. Due to the relatively constant characteristics of antibodies, these results can probably be extended to other molecules of the same family. Conclusions Preliminary results indicate that anodal iontophoresis could be a promising strategy to non-invasively deliver bevacizumab through the sclera. The presence in the eye of other barriers, both static and dynamic, necessitates further evaluation of the technique on more complex ex-vivo and in-vivo models.

Original languageEnglish
Pages (from-to)1189-1194
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Volume62
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Iontophoresis
Sclera
Fluorescein
Antibodies, Monoclonal, Humanized
In Vitro Techniques
Bevacizumab
Intravitreal Injections
Macular Degeneration
Diabetic Retinopathy
Ophthalmology
Thin Layer Chromatography
Fluorescence
Phosphates
Antibodies

Keywords

  • bevacizumab
  • fluorescein isothiocyanate
  • iontophoresis
  • transscleral permeation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

In-vitro permeation of bevacizumab through human sclera : Effect of iontophoresis application. / Pescina, Silvia; Ferrari, Giulio; Govoni, Paolo; MacAluso, Claudio; Padula, Cristina; Santi, Patrizia; Nicoli, Sara.

In: Journal of Pharmacy and Pharmacology, Vol. 62, No. 9, 09.2010, p. 1189-1194.

Research output: Contribution to journalArticle

Pescina, Silvia ; Ferrari, Giulio ; Govoni, Paolo ; MacAluso, Claudio ; Padula, Cristina ; Santi, Patrizia ; Nicoli, Sara. / In-vitro permeation of bevacizumab through human sclera : Effect of iontophoresis application. In: Journal of Pharmacy and Pharmacology. 2010 ; Vol. 62, No. 9. pp. 1189-1194.
@article{f6fdc02a384648a3a8b0f73cb1a6dccc,
title = "In-vitro permeation of bevacizumab through human sclera: Effect of iontophoresis application",
abstract = "Objectives Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used in ophthalmology (off-label) for the treatment of neovascularization in diseases such as diabetic retinopathy and age-related macular degeneration (wet form). Bevacizumab is currently administrated by repeated intravitreal injection, which can cause severe complications; a non-invasive delivery route is therefore desirable. The passive permeation of bevacizumab through isolated human sclera was evaluated and the iontophoretic technique was explored as a method to enhance its transscleral transport in vitro. Methods Bevacizumab was fluorescently labelled using fluorescein isothiocyanate (FITC). Permeation experiments were conducted for 2 h in Franz-type diffusion cells using human sclera as the barrier. The donor compartment contained FITC-bevacizumab (2.5 mg/ml) in phosphate-buffered saline at pH 7.4. In the iontophoretic experiments, a current intensity of 2.3 mA (current density 3.8 mA/cm2) was applied. The permeation samples were analysed with a fluorescence detector (excitation and emission wavelengths were 490 and 520 nm, respectively). The stability of FITC-bevacizumab conjugate was checked by thin layer chromatography. Key findings The main finding of this work is that anodal iontophoresis can significantly enhance bevacizumab transport through isolated human sclera (enhancement factor 7.5), even though the drug is essentially uncharged. Due to the relatively constant characteristics of antibodies, these results can probably be extended to other molecules of the same family. Conclusions Preliminary results indicate that anodal iontophoresis could be a promising strategy to non-invasively deliver bevacizumab through the sclera. The presence in the eye of other barriers, both static and dynamic, necessitates further evaluation of the technique on more complex ex-vivo and in-vivo models.",
keywords = "bevacizumab, fluorescein isothiocyanate, iontophoresis, transscleral permeation",
author = "Silvia Pescina and Giulio Ferrari and Paolo Govoni and Claudio MacAluso and Cristina Padula and Patrizia Santi and Sara Nicoli",
year = "2010",
month = "9",
doi = "10.1111/j.2042-7158.2010.01153.x",
language = "English",
volume = "62",
pages = "1189--1194",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "9",

}

TY - JOUR

T1 - In-vitro permeation of bevacizumab through human sclera

T2 - Effect of iontophoresis application

AU - Pescina, Silvia

AU - Ferrari, Giulio

AU - Govoni, Paolo

AU - MacAluso, Claudio

AU - Padula, Cristina

AU - Santi, Patrizia

AU - Nicoli, Sara

PY - 2010/9

Y1 - 2010/9

N2 - Objectives Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used in ophthalmology (off-label) for the treatment of neovascularization in diseases such as diabetic retinopathy and age-related macular degeneration (wet form). Bevacizumab is currently administrated by repeated intravitreal injection, which can cause severe complications; a non-invasive delivery route is therefore desirable. The passive permeation of bevacizumab through isolated human sclera was evaluated and the iontophoretic technique was explored as a method to enhance its transscleral transport in vitro. Methods Bevacizumab was fluorescently labelled using fluorescein isothiocyanate (FITC). Permeation experiments were conducted for 2 h in Franz-type diffusion cells using human sclera as the barrier. The donor compartment contained FITC-bevacizumab (2.5 mg/ml) in phosphate-buffered saline at pH 7.4. In the iontophoretic experiments, a current intensity of 2.3 mA (current density 3.8 mA/cm2) was applied. The permeation samples were analysed with a fluorescence detector (excitation and emission wavelengths were 490 and 520 nm, respectively). The stability of FITC-bevacizumab conjugate was checked by thin layer chromatography. Key findings The main finding of this work is that anodal iontophoresis can significantly enhance bevacizumab transport through isolated human sclera (enhancement factor 7.5), even though the drug is essentially uncharged. Due to the relatively constant characteristics of antibodies, these results can probably be extended to other molecules of the same family. Conclusions Preliminary results indicate that anodal iontophoresis could be a promising strategy to non-invasively deliver bevacizumab through the sclera. The presence in the eye of other barriers, both static and dynamic, necessitates further evaluation of the technique on more complex ex-vivo and in-vivo models.

AB - Objectives Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used in ophthalmology (off-label) for the treatment of neovascularization in diseases such as diabetic retinopathy and age-related macular degeneration (wet form). Bevacizumab is currently administrated by repeated intravitreal injection, which can cause severe complications; a non-invasive delivery route is therefore desirable. The passive permeation of bevacizumab through isolated human sclera was evaluated and the iontophoretic technique was explored as a method to enhance its transscleral transport in vitro. Methods Bevacizumab was fluorescently labelled using fluorescein isothiocyanate (FITC). Permeation experiments were conducted for 2 h in Franz-type diffusion cells using human sclera as the barrier. The donor compartment contained FITC-bevacizumab (2.5 mg/ml) in phosphate-buffered saline at pH 7.4. In the iontophoretic experiments, a current intensity of 2.3 mA (current density 3.8 mA/cm2) was applied. The permeation samples were analysed with a fluorescence detector (excitation and emission wavelengths were 490 and 520 nm, respectively). The stability of FITC-bevacizumab conjugate was checked by thin layer chromatography. Key findings The main finding of this work is that anodal iontophoresis can significantly enhance bevacizumab transport through isolated human sclera (enhancement factor 7.5), even though the drug is essentially uncharged. Due to the relatively constant characteristics of antibodies, these results can probably be extended to other molecules of the same family. Conclusions Preliminary results indicate that anodal iontophoresis could be a promising strategy to non-invasively deliver bevacizumab through the sclera. The presence in the eye of other barriers, both static and dynamic, necessitates further evaluation of the technique on more complex ex-vivo and in-vivo models.

KW - bevacizumab

KW - fluorescein isothiocyanate

KW - iontophoresis

KW - transscleral permeation

UR - http://www.scopus.com/inward/record.url?scp=77955242157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955242157&partnerID=8YFLogxK

U2 - 10.1111/j.2042-7158.2010.01153.x

DO - 10.1111/j.2042-7158.2010.01153.x

M3 - Article

C2 - 20796199

AN - SCOPUS:77955242157

VL - 62

SP - 1189

EP - 1194

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 9

ER -